Abstract
Sickle cell anemia is an inherited hemoglobinopathy that causes acute and chronic hemolytic anemia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88:932.
Beverung LM, Strouse JJ, Hulbert ML, et al. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90:139.
Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146.
Davies SC, Roberts-Harewood M. Blood transfusion in sickle cell disease. Blood Rev. 1997;11:57.
Goldstein AR, Anderson MJ, Serjeant GR. Parvovirus associated aplastic crisis in homozygous sickle cell disease. Arch Dis Child. 1987;62:585.
Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381:930.
Josephson CD, Su LL, Hillyer KL, Hillyer CD. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. Transfus Med Rev. 2007;21:118.
Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785.
Quirolo K. How do I transfuse patients with sickle cell disease? Transfusion. 2010;50:1881.
Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322:1617.
Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387.
Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81:1109.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Al-Salem, A. (2016). Blood Transfusion Therapy for Patients with Sickle Cell Anemia. In: Medical and Surgical Complications of Sickle Cell Anemia. Springer, Cham. https://doi.org/10.1007/978-3-319-24762-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-24762-5_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-24760-1
Online ISBN: 978-3-319-24762-5
eBook Packages: MedicineMedicine (R0)